TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Petros Grivas, Damien Pouessel, Chandler H. Park, Philippe Barthélémy, Manojkumar Bupathi, Daniel P. Petrylak, Neeraj Agarwal, Aude Flechon, Chethan Ramamurthy, Nancy B. Davis, Alejandro Recio-Boiles, Scott T. Tagawa, Cora N. Sternberg, Astha Bhatia, Cabilia Pichardo, Trishna Goswami, Yohann Loriot
Institutions: University of Washington, Fred Hutch Cancer Center, Institut universitaire du cancer de Toulouse Oncopole, Institut Claudius Regaud, Norton Healthcare, Institut de Cancérologie Strasbourg, Rocky Mountain Cancer Centers, Yale Cancer Center, University of Utah, Huntsman Cancer Institute, Centre Léon Bérard, The University of Texas at San Antonio Health Science Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, University of Arizona Cancer Center, Weill Cornell Medicine, Université Paris-Saclay, Institut Gustave Roussy
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Gilead Sciences
OpenAlex ID: W4213157296